VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.18) by 55.56 percent. This is a 60 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $86.000 thousand which missed the analyst consensus estimate of $200.000 thousand by 57.00 percent. This is a 57.43 percent decrease over sales of $202.000 thousand the same period last year.